Prescription Drugs Market
Prescription Drugs Market - Global Industry Assessment & Forecast
Segments Covered
- By Type Branded, Generic
- By Therapy Area Oncology, Immunology, Ophthalmology, Respiratory, Dermatology, Gastroenterology, Urology, Gynaecology, Endocrinology, Other Therapy Areas
- By Route of Administration Oral, Topical, Parenteral, Other Routes of Administration
- By End-Users Hospitals, Specialty Clinics, Homecare, Other End-Users
- By Distribution Channel Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base Year: | 2022 |
Forecast Years: | 2023 - 2030 |
Historical Years: | 2017 - 2021 |
Revenue 2022: | USD 0.8 Billion |
Revenue 2030: | USD 1.4 Billion |
Revenue CAGR (2023 - 2030): | 8.5% |
Fastest Growing Region (2023 - 2030) | Asia Pacific |
Largest Region (2022): | North America |
Customization Offered
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Sr. No. | Offering | Report Coverage |
1. | Market Size | In terms of Revenue (USD Million) |
2. | Historic Data | 2017 to 2021 |
3. | Forecast Data | 2023 to 2030 |
4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
5. | Market Attractiveness Analysis | Yes |
6. | Segment Analysis | Maximum Segments |
7. | Regional Coverage | 5 Regions |
8. | Country Coverage | Top 22 Countries |
9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
10. | Porter’s Five Forces Analysis | Yes. |
11. | Value Chain Analysis | Yes |
12. | PEST Analysis | Yes |
13. | Regulatory Landscape | Yes |
14. | Technology Landscape | Yes |
15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
16. | Top startups to watch out for | Yes |
17. | Top 3 Trends to Watch | Yes |
18. | Top 3 Strategies Followed by Major Players | Yes |
19. | Top 3 Predictions by Vantage Market Research | Yes |
20. | Discussion Guide | Yes |
21. | Key Primary Respondents - VERBATIM | Yes |
22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
23. | Others/Miscellaneous |
FAQ
Frequently Asked Question
What is the global demand for Prescription Drugs in terms of revenue?
-
The global Prescription Drugs valued at USD 0.8 Billion in 2022 and is expected to reach USD 1.4 Billion in 2030 growing at a CAGR of 8.5%.
Which are the prominent players in the market?
-
The prominent players in the market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline PLC (UK), Novartis AG (Switzerland), Merck & Co. Inc. (U.S.), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (UK), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH (Germany), Dr. Reddy's Laboratories Ltd. (India), Gilead Sciences Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly & Company (U.S.), AbbVie Inc. (U.S.), Lupin (India), Allergan (Ireland).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 8.5% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Prescription Drugs include
- Increasing prevalence of cardiovascular diseases
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Prescription Drugs in 2022.